Anselamimab offers significant reduction in all-cause mortality and cardiovascular hospitalization risk for kappa AL amyloidosis
SOHO Insider Editors
September 9, 2026
The study, led by Ashutosh Wechalekar, MD, of National Amyloidosis Centre and University College London Hospitals in the United Kingdom, analyzed a combined population of patients with stage 3a or 3b AL amyloidosis from two phase 3 randomized trials in the Cardiac Amyloid Reaching for Extended Survival (CARES) program.
